Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
 Bcr-Abl and Lyn protein kinase inhibitor INNO 406, 2 mg  

Bcr-Abl and Lyn protein kinase inhibitor INNO 406, 2 mg

(S)-N-(3-(4,5'-bipyrimidin-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide

INNO 406 is an orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy

More details

PKI-INNO406-002

Availability: within 3 days

130,00 €

Background: INNO 406 is an orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy; orally bioavailable; more potent (>10 times) than Imatinib; highly recommended Abl inhibitor in treating chronic myeloid leukaemia (CML).

Chemical formula: C30H31F3N8O
Molecular weight: 576.62 g/mol
Purity: 99%
Optical purity: Optically pure
Appearance: Off-white solid
Solubility: Soluble in 0.1N HCl(aq) and DMSO
CAS Number: 859212-16-1

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

A Yokota et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 2007, 109(1), 306-314.
 
H Kantarjian et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116(11), 2665-72.
 
JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876.